Phathom Pharmaceuticals, Inc. (PHAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 12, 2026, Robert Breedlove, Vice President, Finance and principal accounting officer, of Phathom Pharmaceuticals

Event · Exec change
Person
Robert Breedlove
Title
Vice President, Finance and principal accounting officer
Action
resigned
Effective
December 4, 2026

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 18, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PHAT
Neutral
low confidence
Mentioned
$PHAT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PHATNeutralLow
01

Why it matters

Minimal impact on valuation; investors may monitor subsequent appointments.

02

Market read

Limited relevance for traders; primarily of interest to current shareholders.

03

What to watch

Potential hidden restructuring or cost‑cutting plans not disclosed in the filing.

Relevance 6/10Novelty 2/10Timing: effective Dec 4 2026

Background

The filing is a standard SEC Form 8‑K announcing an executive departure, typical for public companies.

Company-level read

Ticker impact

$PHATNeutralLow confidence
Context

SEC 8‑K reports Vice President of Finance Robert Breedlove resigns effective Dec 4 2026.

Expected impact

likely slight downside as market prices in the leadership change

Evidence & confidence

Officer resignation is a routine corporate action for a micro‑cap; no strategic shift disclosed.

Market effects

none

none

none

Counterpoint

The resignation may be a catalyst for a short‑term rally if investors view it as an opportunity for new leadership.

Key entities

  • Robert Breedlove

    Vice President, Finance and principal accounting officer resigning

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.